Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential COVID-19 vaccine.
There is a notable name missing from the frontrunners in the race to test experimental immunisations against the novel coronavirus: the world’s largest vaccine maker GlaxoSmithKline
The world’s largest vaccine maker said it was in talks with governments to back a manufacturing expansion that would help to scale up production of future vaccines for COVID-19
LONDON: Pharmaceutical giants GlaxoSmithKline and Pfizer on Wednesday announced a merger of their consumer healthcare units that produce over-the-counter medicines. GSK said it would have a 68-percent controlling equity interest in the joint venture that will have combined sales of about £9.8 billion ($12.7 billion, 10.9 billion euros). The deal paves the way for British group GSK to have two UK-listed companies, one specialised in the development of drugs and the other in consumer healthcare. It comes as the…
LONDON: GlaxoSmithKline notched up a second win for its pioneering "real world" approach to testing new drugs on Friday as its inhaled medicine Breo proved significantly better than standard care in helping people with asthma. The success of the 4,233-patient trial, which tested Breo in day-to-day practice across the town of Salford in northern England, follows a similar win for the medicine in chronic obstructive pulmonary disease (COPD) a year ago. The study showed the drug, which is marketed as Relvar in Europe, was…
SEATTLE: Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir. Gilead's bictegravir, another so-called integrase inhibitor drug, delivered 97 percent virus suppression, making it just as effective as GSK's product, data presented at a medical meeting in Seattle late on Monday showed. Importantly, there were no cases of resistance emerging to the new medicine in the 98-patient…
LONDON: GlaxoSmithKline is cutting the price charged for its pneumococcal vaccine when given to refugees, following complaints about the product's "exorbitant" cost by medical charity Medecins Sans Frontieres.